Quantifying influenza shedding duration, a possible predictor of infectivity and transmissibility, can inform infection prevention and control measures [1] . Several factors, such as age and to a lesser extent human immunodeficiency virus (HIV) status, have been found to impact shedding duration [2, 3] . Early studies suggested HIV-infected adults may shed influenza longer [2, 4] , while more recent studies found that HIV-infected adults shed for a similar time to HIV-uninfected adults, possibly due to higher CD4 counts and virological suppression in the era of widespread antiretroviral therapy (ART) availability [5] . South Africa has a significant HIV epidemic, with an estimated 7.1 million children and adults living with HIV and 3.9 million individuals on ART in 2016 [6] . The mean CD4 count at time of first presentation and diagnosis in South Africa is approximately 250 cells/µL [7] . Differential shedding duration by HIV status and CD4 count is important to determine as prolonged influenza shedding may be associated with viral evolution and antigenic drift within a patient [8] , the development of resistance to influenza antivirals following therapy [9] , and an increased transmissibility.
Adult studies have reported a range of influenza virus shedding durations using mainly real-time reverse transcription polymerase chain reaction (rRT-PCR) assays, with a shorter duration reported in healthy versus hospitalized adults [1, 10] . A longer duration of shedding is often described in children and immunocompromised individuals [2] . In children the median duration of virus detection is usually 7-8 days, but may be longer [11] .
Influenza virus shedding data from Africa, in particular countries with high HIV prevalence, are limited. One study from Kenya explored shedding patterns of influenza A(H1N1) pdm09 in 106 patients with low known HIV prevalence [12] . The median duration of influenza virus detection was 8 days using rRT-PCR.
There are minimal data regarding the impact of HIV infection on influenza virus shedding duration [5] . We aimed to evaluate whether seasonal influenza virus shedding duration and viral load (VL) differed between HIV-infected and -uninfected individuals with influenza-like illness (ILI) in 2 provinces of South Africa in 2012-2014.
METHODS

Study Design and Setting
We conducted a prospective cohort study of individuals older than 6 months of age, during 3 consecutive influenza seasons (2012) (2013) (2014) . Patients who met the case definition for ILI, that is presenting to an outpatient clinic with sudden onset of fever (>38°C) and cough or sore throat in the absence of another diagnosis, and who had onset of symptoms in the last 3 days, were actively identified (active case ascertainment) at public primary health care clinics in 2 provinces (Edendale, KwaZulu Natal and Klerksdorp, North West Province). Respiratory samples from consenting eligible patients were tested with a rapid diagnostic test for influenza (BD Directigen EZ Flu A+B or BD Veritor [Becton, Dickinson and Company, MA]). Recruitment was restricted to patients presenting within 72 hours of symptom onset as influenza viral load usually peaks during the first 24-72 hours of illness.
Patients younger than 5 years of age had a nasopharyngeal aspirate taken while patients 5 years or older had a nasopharyngeal swab and oropharyngeal swab taken as per the routine surveillance program (described elsewhere) [13] that the shedding study was nested within. Specimens were submitted to the National Institute for Communicable Diseases (NICD) in Johannesburg in PrimeStore Molecular Transport Medium (Longhorn Vaccines and Diagnostics, Bethesda, MA) for multiplex rRT-PCR testing and confirmation of influenza infection. Patients whose enrolment specimen tested positive for influenza on rapid test, but negative on rRT-PCR, were excluded from the shedding study. Respiratory specimens were collected from patients whose enrolment sample tested positive for influenza by rRT-PCR every 2 days for the first 2 weeks (day 14) after enrolment and then at 21 days from the date of enrolment (influenza confirmation). A second rapid test was done on the day 21 respiratory specimen and if it tested positive another sample was taken on day 28. Patients were considered to be no longer shedding if specimens were negative for influenza by rRT-PCR at 2 consecutive visits. Symptom onset at the initial visit and the presence of symptoms at all study follow-up visits were recorded.
For HIV status, any documented or verbal confirmation was accepted for a positive status. For a negative status, if the patient had no recent documented proof of their status and they consented to a test, pretest counseling and testing for HIV was offered by study staff. If no consent for testing was given, the patient's HIV status was recorded as unknown. HIV-infected patients also had blood drawn for CD4 count.
Laboratory Diagnosis
A multiplex rRT-PCR assay detecting 10 respiratory viruses (influenza A and B viruses, para-influenza viruses 1-3, respiratory syncytial virus, enterovirus, human metapneumovirus, adenovirus, and rhinovirus) was used for confirmation of influenza virus infection [14] . Influenza A positive samples were subtyped using an assay developed by the Centers for Disease Control and Prevention (CDC), Atlanta [15] , and influenza B viruses were lineage typed by rRT-PCR assay [16] . Influenza A and B VLs were determined for positive specimens for all visits using the CDC rRT-PCR as a quantitative assay by including a series of standards of known copy numbers [17] . We considered a cycle threshold (Ct) value cutoff of ≤37 as a positive rRT-PCR result [18] .
Durations of Symptoms and Shedding
We defined symptom duration as time from symptom onset to the first day on which the relevant symptom was resolved, based on participant report. The respiratory symptom category included sore throat, cough, and rhinorrhea; the all-symptom category included respiratory symptoms plus fever and myalgia; and fever alone was reported as a separate symptom category [19] . The duration of influenza viral shedding was considered as the number of days from onset of symptoms to last positive influenza rRT-PCR result.
Statistical Analysis
We compared baseline characteristics of enrolled HIV-infected and -uninfected participants using a multivariable logistic regression model. We started with all variables significant at P < .20 on univariate analysis, and dropped all nonsignificant factors (P ≥ .05) with manual backward elimination. Patients with missing data for included variables were dropped from the model (data were >90% complete for all variables except CD4 count).
Time from symptom onset to (1) last day of influenza virus detection on rRT-PCR and (2) alleviation of symptoms was analyzed using Kaplan-Meier estimates and Weibull accelerated failure time regression models, which allow explanatory variables (eg, age, sex, HIV status, influenza virus type/subtype, underlying medical conditions, antibiotic use, study site, study year) to proportionally increase or decrease time to endpoint [20] . The Weibull accelerated failure time model allowed more flexibility than a Cox semiparametric model as the associated hazard rate was not constant with respect to time; the Weibull model was a better fit for our data. Hazard ratios measured the hazard of becoming PCR negative with a ratio <1 indicating a longer duration of shedding.
Influenza viral RNA load data (expressed in copies/mL) for the enrolment visit was log 10 transformed. Mann-Whitney U tests were used to explore the difference in initial VLs between HIV-infected and -uninfected individuals. All statistical analyses were performed using STATA version 14.1 (StataCorp, College Station, TX).
Ethical Approval
The protocol was approved by the University of the Witwatersrand (M120129), University of KwaZulu-Natal (BF079/12) ethics committees, the relevant Provincial Departments of Health and the US Centers for Disease Control and Prevention. All study participants or parents/guardians (for children <18 years) were required to sign an informed consent form.
RESULTS
A total of 4214 patients were enrolled into the ILI surveillance program during 3 consecutive influenza seasons (MayOctober) (Figure 1 ). In 2012, study screening only started in August in Edendale following ethics approval. Overall, 1152 patients were ineligible as they were younger than 6 months of age (n = 160) or reported presence of symptoms for more than 3 days prior to the visit (n = 992). Of the remaining 3062 (73%) ILI patients, 867 (28%) patients were not screened (lack of rapid tests or left clinic) and 23 patients (1%) refused consent. Only 2172 patients were screened with a rapid test and 1813 (83%) tested negative. Of the patients with a negative rapid test result, 16% (283/1813) were false negatives (positive for influenza on rRT-PCR). Of the 359 patients whose screening rapid test was positive, 26% (95/359) were subsequently reported to be negative for influenza on rRT-PCR, resulting in 264 patients enrolled in the study (Figure 1 4 ; 45-64 years aOR 49.9; 95% CI, 6.7-373.1; compared with age <5 years), to be female (aOR 3.5; 95% CI, 1.5-8.5), and to have received treatment for tuberculosis in the last 12 months (aOR 36.9; 95% CI, 4.7-289.1), but were less likely to live in a crowded household with more than 3 people per room (aOR 0.2; 95% CI, 0.1-0.8). Only 1 patient (HIVuninfected adult) was vaccinated for influenza in the last year. No patients received oseltamivir treatment or any other agents with anti-influenza activity as part of routine care.
Duration of influenza shedding did not differ significantly (P = .84) between HIV-infected (median days 6, interquartile range [IQR] 3-11) and -uninfected individuals (median days 7, IQR 4-11) (Figure 2A) . Symptom duration was similar between HIV-infected and -uninfected individuals for all symptoms (median days 16, IQR 7-21; and 15, IQR 9-18), respiratory symptoms (median days 16, IQR 10-18; and 15, IQR 11-18), and fever (median days 7, IQR 3-14; and 5, IQR 3-12). Fever duration was similar to viral shedding duration while respiratory symptom duration was generally longer (Table 1) .
Factors Associated With Duration of Influenza Virus Detection by rRT-PCR
Overall, the median duration of influenza virus detection by rRT-PCR was 7 days (IQR 3-11 days). On multivariable analysis ( Table 2) , duration of detection of influenza virus by rRT-PCR differed by age group ( Figure 2B ), with longer detection in children aged <5 years compared with adults ≥45 years (adjusted Only parameters significant on multivariable analysis are shown in the table. Bold indicates significant variables. Median duration of influenza shedding and symptoms are also shown.
The following additional variables were evaluated but not found to be significant on univariate analysis: study year, study site, race, underlying medical conditions, and influenza subtype. We were unable to demonstrate a difference in virus detection by rRT-PCR with regards to influenza vaccination use as only 1 individual was vaccinated in our cohort. When restricting to HIV-infected individuals (Table 3 and Figure 2D ), on multivariable analysis influenza virus detection by rRT-PCR was significantly longer in individuals with CD4 counts ≤200 cells/µL compared to those with CD4 counts >200 cells/µL (aHR 3.55; 95% CI, 1.05-12.08) and older adults (aged ≥45 years) were more likely to shed for longer than children aged <5 years (aHR 26.75; 95% CI, 2.50-286.68). ART use was not significant in the final multivariable model. A subgroup analysis in individuals aged ≥5 years (data not shown), showed no difference in detection between the adult age groups, but the difference by CD4 count (longer in individuals with lower CD4 counts, aHR 3.45; 95% CI, 1.02-11.69) was retained.
Factors Associated With Duration of Symptoms
On multivariate analysis of factors associated with the duration of all ILI symptoms (Table 4) , children <5 years (HR 0.53; 95% CI, 0.34-0.84), children 5-14 years (HR 0.52; 95% CI, 0.34-0.81), and adults aged 25-44 years (HR 0.57; 95% CI, 0.34-0.94) had a longer duration of symptoms than individuals aged 15-24 years. In addition, participants from Edendale reported ongoing symptoms for a shorter duration (aHR 1.65; 95% CI, 1.20-2.28) than those from Klerksdorp. On comparison, the 2 sites had similar characteristics except for a difference in the proportion of patients enrolled across the 3 years. There was no difference in duration of symptoms by HIV status (HR 0.84; 95% CI, 0.58-1.22) or CD4 count (not included in final model). Log-rank test for equality of survivor functions: HIV status P = .86; Age group P = .17; Influenza subtype P = .02; CD4 count P = .14. Similar results were found when we explored factors associated with respiratory symptoms and fever separately.
Comparison of Initial Influenza Viral Loads
There were 112 HIV-uninfected and 35 HIV-infected individuals with initial influenza VL measurements. The VL for HIV-uninfected subjects at the initial visit was a mean (standard deviation) of 5.28 ± 1.33 log 10 copies/mL, while for HIVinfected subjects it was 4.73 ± 1.68 log 10 copies/mL (P = .08). When restricting to HIV-infected individuals no difference in initial influenza VL was noted by CD4 count levels (P = 1.00). Initial influenza VLs did, however, differ by influenza subtype: A(H1N1)pdm09 (n = 33, 5.67 ± 1.27 log 10 copies/mL) and A(H3N2) (n = 93, 4.71 ± 1.39 log 10 copies/mL, P < .001).
DISCUSSION
Our study found no overall difference in the duration and intensity at baseline of influenza virus shedding as detected by rRT-PCR in HIV-infected compared to HIV-uninfected individuals. We did, however, find some evidence that HIV-infected immunocompromised individuals with lower CD4 counts may shed for longer than HIV-infected individuals with higher CD4 counts, although numbers were small. It is important to understand transmission dynamics to prevent transmission to these groups as the effectiveness of influenza vaccine in severely immunocompromised individuals has not been established and prolonged antiviral use may lead to the development of resistant mutants [21] . Amongst ILI patients with laboratory-confirmed influenza, when compared to HIV-uninfected individuals, HIVinfected individuals were older in age due to extremely low HIV-positivity rates in children aged <5 years (3%); this was likely due to improvements in prevention of mother-to-child transmission programs [22] . HIV-infected individuals were more likely to be female, which has been shown from other South African data, and is ascribed to biological vulnerability and sociobehavioral factors [23] . Lastly, HIV-infected individuals were more likely to have had tuberculosis in the last year than HIV-uninfected individuals, consistent with the known high rate of HIV/ tuberculosis coinfection [24] .
Most data regarding the duration of shedding in immunocompromised individuals have been obtained from patients with conditions other than HIV [2, 21, 25, 26] . Studies in cancer patients on chemotherapy and other immunocompromising conditions have shown prolonged shedding of influenza viruses, ranging from 2 weeks to 18 months, and a higher incidence of drug-resistant viruses than immunocompetent individuals [21] . HIV-infected individuals have been shown to develop more-severe influenza disease with higher mortality, especially in individuals with more-advanced HIV disease [27] [28] [29] . A study in 20 HIV-infected adults diagnosed with influenza reported a median duration of influenza detection by rRT-PCR of 10 days (IQR 6-15 days) and a median duration of any ILI symptoms of 14 days (IQR 12-26 days) [5] . The majority of these patients were virologically suppressed on ART and results did not differ from previous studies in HIV-uninfected individuals. Our study, which systematically enrolled ILI patients testing positive for influenza, showed a median duration of influenza detection by rRT-PCR in HIV-infected individuals of 6 days (IQR 3-11 days) and 16 days (IQR 7-21 days) for any ILI symptom; neither differed significantly from the HIV-uninfected group in our cohort. a All symptoms included respiratory symptoms (sore throat, cough, and rhinorrhea) plus fever and myalgia.
In our study, for all individuals we showed longer influenza virus shedding in children aged <5 years compared with adults. However, in HIV-infected individuals only, adults were more likely to shed for longer when controlling for degree of immunosuppression. A systematic review [30] showed longer duration of viral shedding measured by rRT-PCR in children in 3 studies [19, 31, 32] but longer shedding in adults in 2 studies [33, 34] . A significant amount of diversity has been noted in estimates of duration of influenza viral shedding, especially in children [35] . Influenza severity and symptoms have been shown to differ by age group, with more-severe disease in young children and the elderly [36] ; our study found that the duration of all symptoms differed by site and age group, with children having a longer duration of symptoms than young adults.
Other studies have demonstrated similar patterns of viral shedding between pandemic and seasonal influenza A [19] and different subtypes of seasonal influenza A viruses [35] . We demonstrated a difference in the initial VLs of seasonal influenza A as well as a difference in the duration of shedding.
Our study had a number of limitations. First, we used a case-ascertainment study design in which potential participants who met the ILI case definition were recruited from outpatient clinics and an influenza rapid test was used to detect patients testing positive for the influenza virus. Such recruitment may have led to bias in participant selection as individuals had illness that was severe enough to seek medical attention with a positive rapid test result, and may thus have had higher levels of viral shedding [37] . Second, it is unclear whether health-seeking behavior differed between the HIV-infected and -uninfected individuals identified with influenza in our study. We were not able to assess whether HIV is more likely to cause a clinical illness that warrants seeking care, nor were we able to exclude that there may be differential shedding among HIVinfected and -uninfected individuals ascertained in the community. We are currently conducting a community based study of influenza burden and transmission at 2 sites in South Africa, which may provide answers to some of these outstanding questions [38, 39] . Third, we had more false-positive rapid test results than previous studies [40] ; this resulted in us having to follow-up more patients until their rRT-PCR results were available. We also tried to enroll patients who were rapid test negative and rRT-PCR positive, but this was only possible if the rRT-PCR results were available before the day 2 follow-up visit. We, however, only retained individuals in the study who tested positive on rRT-PCR. Fourth, we only measured the duration of viral shedding by rRT-PCR and not by virus isolation in cell cultures. This may have overestimated the duration of shedding in our study as culture only detects viable virus whereas rRT-PCR detects any viral particles present in the sample, thus detecting RNA remnants of past infection without active replication. The mean duration of viral shedding is reported as 1.5-6 days shorter when measured by culture compared with rRT-PCR and virus isolations are usually obtained from positive rRT-PCR specimens with a Ct value ≤30 [19, 41, 42] . Lastly, we had low numbers of HIV-infected individuals, especially young children, enrolled in the study, with available CD4 count results only in two-thirds as these bloods were processed in routine hospital laboratories. However, of those patients with known results nearly 90% had CD4 counts of more than 200 cells/ µL and were seen with mild symptoms at general outpatient clinics; it is therefore likely that overall enrolled patients were mildly immunosuppressed accounting for the lack of difference in shedding duration between HIV-infected and -uninfected individuals.
Our study also had a number of strengths. We enrolled both HIV-infected and -uninfected individuals of all age groups from the same population; we enrolled participants over multiple seasons with different predominating influenza types; participants were actively followed up and swabbed every 2 days for 2 weeks and then weekly; and we assessed both quantitative and qualitative measures of viral shedding.
In conclusion, in the era of an established ART program we did not show any difference in influenza virus shedding as detected by rRT-PCR in HIV-infected and -uninfected individuals in outpatient clinics in 2 areas of South Africa. We did, however, show a potential difference in influenza virus shedding by CD4 count with individuals with lower counts shedding for longer. Even though the efficacy of the influenza vaccine in severely immunocompromised individuals is unclear, prior data from South Africa demonstrated that the trivalent influenza vaccine was efficacious in HIV-infected individuals with CD4 counts >100 cells/µL [43] . Influenza vaccination is recommended and offered as part of an annual government-funded campaign for HIV-infected individuals in South Africa to reduce the incidence of severe disease; however, none of the HIV-infected individuals in our study had received the vaccine in the last 12 months. Although antiviral medication for influenza is recommended for high-risk groups it is not widely available in public health clinics in South Africa. In addition to influenza-specific prevention and treatment strategies, it is vital that severely immunocompromised HIV-infected individuals are given appropriate ART to prevent a potential increased risk of influenza transmission and resistant mutations. 
